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Because Docetaxel has both radiosensitizing
properties as well as good anticancer activity by
itselt in squamous celi carcinomas we are going
to attempt concurrent use ot Docetaxel and
radiochemiotherapy in patients with advanced
head and neck cancers (HNC).
Aim: The objective ot this study is to evaluate
the response rate, loco-regional control, disease
- tree survival and overall survival in previously
untreated inoperable HNC patients.
Methods: This is a project ot an open non-
randomized, one centre, phase II, one arm
study. Total planned dose ot RT tor GTV is 68
Gy given in 40 tractions, once daily, 7 times per
week concomitantly with Cis-Platin, Navelbine
and Docetaxel. Eligibility criteria include: proven
HNC not treated betora, good performance
status, normaI bone marrow, liver and renal
tunction, age bellow 60. The regimen is
proposed as tollows: Cis-Platin Lv. 70mg/m2 on
day 1, 22, 43, 64, Navelbine 20mg/m2 Lv. on day
1, 8, 22, 29, 43, 50, 64 and Docetaxel 30
mg/m2lweek or as 1-h intusion ot 60 mg/m2 in
each 7 days ot RT, Ethyol 1000 mg Lv. on day
1, 22, 43 and 250 mg on day 23 - 42.
Radiotherapy 1,7 Gy per traction continuously
on day 23 - 42 and 44 - 63. Different treatment
schedules ot Docetaxel could be used on the
basis ot cellular activity tor a given tumour. So,
biopsy should be obtained tor analysis ot pre-
treatment levels ot apoptosis and oncogenes
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Aim: The assessment ot the early tailure and
toxicity ot treatment tor the advanced NSCLC
using the accelerated hyperfractional contormal
irradiation _
Material: 13 patients (12 men, 1woman, aged
50 - 74), in good performance status/70-90
points ot Karnotsky scale 1 were treated.
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Patients have been irradiated with 15 MV or 6
MV photon two times a day with 6 hours break
using 1.25 Gy traction to total dose 50 Gy. PTV
ranged trom 599 to 1104 cm3 (mean 858cm3).
Methods: The mean tumor dimension betore
and 6 weeks after tinishing treatment with the
use ot CT have been assessed.
Results: 3 early tailure have been observed,
all outside ot PTV. The 2/3 ot that recurrence
have been recognized by eT. These patients
have been ordered to chemotherapy. The mean
tumor dimension was equal to 2,38 cm 6 weeks
after tinishing ot treatmen1. This means 44%
regression ot the mean tumor dimension. No
side effects and deteriorations ot performance
status have been observed.
Ali patients have tinished the treatment, all are
in tollow up, alive.
Conclusions: The accelerated hyperfractioned
regimen can be carried out in outpatients service
it PTV is smaller than 1000cm3•
Observed early recurrence two months ot
tollow up are connected with a progression ot a
tumor outside ot irradiated volume.
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RETROSPEKTYWNA OCENA
WCZESNYCH I PÓŹNYCH ODCZY-
NÓW POPROMIENNYCH W ŚLUZÓW­
KACH JAMY USTNEJ PO POOPERA-
CYJNYM NAPROMIENIANIU Z PO-
WODU RAKA PRZYUSZNICY
Z. Laskus
Klinika Nowotworów Głowy i Szyi
Centrum Onkologii, Warszawa
Cel pracy: ocena częstości rejestrowanych
odczynów i ich wpływu na jakość życia pacjenta.
Materiał i metoda: W II Zakł. Teleterapii
w latach 1984-1997 leczono 86 chorych z rakiem
przyusznicy. Zebrano retrospektywne dane
z zapisu w historiach chorób, dotyczące
pojawienia się, trwania i nasilenia wczesnych
późnych odczynów popromiennych
w śluzówkach. Oceniono teź przeżycia chorych
(60% przeżyć 5-cioletnich) i porównano je
z danymi z literatury dotyczącymi przeżyć
u pacjentów leczonych samodzielną chirurgią
(20-30% przeżyć 5-cioletnich).
Wyniki: Odczyn wczesny w śluzówkach
opisano u 50 chorych (58%), odczyn późny
u 17 chorych (19,8%). Wyraźną kserostomię
(przejaw odczynu późnego II stopnia) klinicznie
stwierdzono u 2 chorych, w tym po 2 latach
od rozpoczęcia leczenia - u 1 chorego. Częstą
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